Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts
Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts
評估ANI製藥：來自5位金融分析師的見解
ANI Pharmaceuticals (NASDAQ:ANIP) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
在過去的三個月中，有5位分析師對ANI Pharmicals（納斯達克股票代碼：ANIP）進行了分析，揭示了從看漲到看跌的不同觀點。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表總結了他們最近的評級，展示了過去30天內不斷變化的情緒，並將其與前幾個月進行了比較。
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $77.8, with a high estimate of $83.00 and a low estimate of $72.00. Observing a 9.19% increase, the current average has risen from the previous average price target of $71.25.
分析師對12個月目標股價的評估提供了更多見解，顯示平均目標價爲77.8美元，最高估計爲83.00美元，低估值爲72.00美元。目前的平均價格上漲了9.19％，已從之前的平均目標價71.25美元上漲。
Interpreting Analyst Ratings: A Closer Look
解讀分析師評級：仔細觀察
A clear picture of ANI Pharmaceuticals's perception among...
通過對分析師近期行...
登入免費觀看全文
登入/註冊